Latest News
& Press Releases
Browse the latest news from BioSpace, and press releases from around the industry. Want to filter by date, keyword, and more? Search here.
TOP STORIES
Although COVID-19 appears to be on the run in the U.S., there is still a threat of resurgence. Here’s a look at some of the most recent COVID-19 stories and research.
BridgeBio released early data from its Phase I/II CANaspire clinical trial, indicating that BBP-812 might be a promising gene therapy for the ultra-rare Canavan disease.
The WHO will decide whether to declare a public health emergency following the recent outbreaks of monkeypox, and poliovirus has been detected in London water samples.
In addition to patent cases, partnerships and pledging money to global tropical disease efforts, Novartis scored a win on a combo-treatment for solid tumors.
Regeneron has broken ground on a $1.8 billion expansion of its Tarrytown, NY facilities that will add at least 1,000 new full-time jobs.
DEM BioPharma has $70 million to get started on novel immunotherapeutics to treat cancer following a successful financing round.
According to a recent report, the New York City Metro area is home to 7% of the U.S. population but contains 10% of all U.S. biochemists and biophysicists and 12% of U.S. chemists.
PhaseBio is working toward mitigating the surgical risks for cardiac patients taking antiplatelet therapies with bentracimab, which is currently in Phase III development.
Funding for life sciences companies picked up this week as investors pumped new money into firms developing treatments for spinal muscular atrophy (SMA), immuno-oncology, allergies and rare diseases.
Olink said the measurement of proteins at “population scale” provides the ability to improve the understanding of underlying mechanisms of diseases.
Takeda announced it secured 600,000 square feet of research and development and office space in new construction at Cambridge’s Kendall Square.
Enanta filed a patent infringement lawsuit against Pfizer for the latter’s alleged use of its proprietary antiviral component in producing the COVID-19 antiviral Paxlovid.